Therapeutic Candidates

RR MedSciences Lead Product

Lead Therapeutic

RRMed has advanced a novel analgesic leveraging its patented small molecule drug RM191A, for the treatment of Neuropathic Pain. This innovative pain relief treatment is non-addictive, non-opioid and formulated as a topical medicine. 

Neuropathic (nerve) pain is a condition of unmet need globally, lacking fully effective, safe medications. This life altering condition stems from a variety of causes. Neuropathic pain may occur as the result of surgery, trauma, HIV, diabetes and chemotherapy and is experienced commonly by cancer survivors. 

Neuropathic pain is often chronic and does not respond effectively to current model of care drugs. The high levels of chronic pain and discomfort results in a profound cost to personal wellbeing. In the USA alone, the market for pain relief associated with neuropathic pain is $3.6 billion USD a year to treat half of the suffering population, with the other half deriving no benefit from existing treatments.

Phase 2a Trial Completed

RRMed’s Neuropathic Pain candidate, RM191A in a novel gel formulation, has recently completed a Phase 2a Clinical Trial at the Pain Management Research Centre at the Kolling Institute, Royal Northshore Hospital, Sydney Australia.

The gold standard double-blind, cross-over placebo controlled trial allowed the participants, who experienced severe symptoms for more than 3 months, to continue their prescribed medications throughout the clinical trial. The affect achieved by RR MedSciences’ candidate can then be seen as a potential therapeutic support for people remaining on their current regimen or as a separate therapy.

RR MedSciences anticipates publishing the results of this Neuropathic Pain Phase 2a Trial which will be available soon.

Clinical Significance

Successful clinical trials of this novel topical analgesic would allow clinicians a new tool to support patients’ chronic pain in a safe and effective manner and provide a doorway to their improved quality of life, with an alternative to the use of opioid or addictive drugs or therapies that have significant side effects.

Market Need

Chronic pain is a widespread condition and affects as many as 100 million people in the US alone. Total economic and direct healthcare costs for treating pain in the US have been estimated to be as high as $635 billion annually in 2018 studies, higher than the costs associated with cancer, Alzheimer’s, or cardiovascular disease.

Welcome

RR MedScirences Newsletter

Please join our email list for company news and updates.